Immunomedics, Inc. (IMMU): Price and Financial Metrics
IMMU Price/Volume Stats
| Current price | $87.86 | 52-week high | $87.93 |
| Prev. close | $87.82 | 52-week low | $8.80 |
| Day low | $87.59 | Volume | 15,318,600 |
| Day high | $87.93 | Avg. volume | 4,013,131 |
| 50-day MA | $67.34 | Dividend yield | N/A |
| 200-day MA | $37.03 | Market Cap | 20.31B |
IMMU Stock Price Chart Interactive Chart >
Immunomedics, Inc. (IMMU) Company Bio
Immunomedics, Inc. focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company was founded in 1982 and is based in Morris Plains, New Jersey.
Latest IMMU News From Around the Web
Below are the latest news stories about Immunomedics Inc that investors may wish to consider to help them evaluate IMMU as an investment opportunity.
Gilead Makes A Sizeable Bet On ImmunomedicsTrodelvy. Source: Fierce Pharma Gilead (GILD) just unpacked part of its $21 billion war chest to acquire Immunomedics (IMMU) for $21 billion. "The agreement will provide Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate ((ADC)) that was granted accelerated approval by the U.S. Food and Drug Administration... |
Immunomedics' trodelvy shows 27% response rate in urothelial cancerImmunomedics (IMMU) announced positive results from cohort 1 (n=113) of cisplatin-eligible patients in Phase 2 TROPHY U-01 study of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC).Results confirmed the interim findings and prior Phase 1/2 study results showing Trodelvy has significant activity and is safe in patients with heavily-pretreated mUC... |
The Week Ahead In Biotech: Conference Presentations, IPOs In The MixBiotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccine/antibody candidates catalyzing some strong moves. A big-ticket M&A was announced at the start of the week. Gilead Sciences Inc. (NASDAQ: GILD agreed to buy Immunomedics Inc. (NASDAQ: IMMU ), which has a commercial antibody drug conjugate in the market. Three biopharma companies and a dialysis equipment maker debuted on Wall Street, with the former group raising combined gross proceeds of $522 million. Here're the catalytic events for the unfolding week: Conferences 56th annual meeting of the European Association for the Study of Diabetes, or EASD: Sept. 21-25 2020 American Academy of Neurology Science Highlights: Sept. 23-24 14th annual ... |
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain CancersResults include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM) |
Wachtell regains top M&A perch, leapfrogging Latham for nowWith the fourth quarter fast approaching, Wachtell, Lipton, Rosen & Katz has passed Latham & Watkins to once again become the top U.S. M&A adviser based on transaction value for 2020, after advising biotech company Immunomedics Inc on its agreement to be acquired by Gilead… |
IMMU Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 432.48% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | 48.28% |
Loading social stream, please wait...